dr aaditya recent advances in immunopharmacology 30 jan10
DESCRIPTION
Sorry, Some of the animations will not work BUT I am allowing download of this ppt :-)TRANSCRIPT
Recent Advances in Immunopharmacology
Dr Aaditya
Immumopharmacology
Understanding Immunology
Modulating immune
response
Humoral Immune response
Polyclonal Abs Monoclonal Abs
Cell mediated immune response
Interleukins & other agents
Evaluating Immunological
Agents
Recent markers and parameters
Rules and regulations
08/04/2023 Dr Aaditya 2
THE NORMAL IMMUNE RESPONSE
08/04/2023 3Dr Aaditya
Immunity Ability to resist almost all types of organisms or
toxins that tends to damage the tissues or organ.
Immunity
Innate Acquired
Active Passive08/04/2023 4Dr Aaditya
08/04/2023 5Dr Aaditya
T- Cell Activation
Signal I- MHC binding With TCR
Signal II- ligation of co-stimulatory molecule CD 40, CD80 with to CD 40L, CD 28 respectively
08/04/2023 6Dr Aaditya
T- Cell Activation
• Negative feed-back loop T-lymphocyte – associated antigen 4 (CTLA-4)
• Following binding of CD28 with CD80 or CD 86, CTLA-4 is mobilised to cell surface were because of its higher affinity for CD80, 86 it outcompetes or displaces CD 28 and results in suppression of T- cell activation & proliferation
08/04/2023 7Dr Aaditya
IPILIMUMAB
• Recombinant humanized antibody that binds CTLA- 4 and prevents its association with CD 80, 86.
• So, the activated state of T- cells is sustained• Tried in patients of Malignant Melanoma• Showed objective improvement in some• S/E development of autoimmune toxicity
08/04/2023 8Dr Aaditya
ABATACEPT• Recombinant fusion protein composed of the
extracellular domain of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) fused to human IgG Fc
• This fusion protein blocks activation of T cells by binding to CD80 or 86 so that CD28 on T cells cannot bind and stimulate the T cell and lead to cytokine release
• Approved for patients with severe rheumatoid arthritis who have failed other DMARDS
08/04/2023 9Dr Aaditya
08/04/2023 10Dr Aaditya
RECENT EVALUATION TECHNIQUES
08/04/2023 11Dr Aaditya
Anti Inflammatory Models
Receptor binding activity
Substance P
3H-Bradykinin
The Tachykinin Family
Neurokinin
Assays of Migration and aggregation
Polymorphonuclear leukocyte
chemotaxis
Cytokines
Flow cytometry
TNF antagonism
08/04/2023 Dr Aaditya 12
Immuno-modulatory Activity
Proliferation of Cells
PFC (plaque forming colony)
Chemoluminescence in macrophages
Mitogen Induced Lymphocyte Proliferation
Autoimmune Response
CTLA-4 Knockout Mouse
Hypersensitivity in animals
Organ Transplant
Acute GVHD in rats
Inhibition of allogenic transplant
rejection
Influence on SLE-like disorder in MRL/lpr
mice
08/04/2023 Dr Aaditya 13
MARKERS USED IN IMMUNOPHARMACOLOGY
08/04/2023 Dr Aaditya 14
Traditional markers
• Total leukocyte count• Differential count• Neutrophil/Lymphocyte Ratio• T-cell CD4+/CD8+ Ratio• T-cell CD4+CD45RO+ expression• Plasma glutamine• Plasma urea• Salivary IgA08/04/2023 Dr Aaditya 15
Newer markers of immune response
• Plasma Cytokine levels– In fever, shock TNF, INF-γ, IL-1,2,6,10
• The soluble receptors of IL-2 (sIL-2R) and tumor necrosis factor (sTNF-R55 and sTNF-R75)– In suspected childhood maleria
• Serum levels of β2-microglobulin, neopterin– In HIV 1& 2 patients
• TNF, INF-γ, receptors of IL-2 (sIL-2R) etc– Used to determine chemotherapy regimen in
cancer08/04/2023 Dr Aaditya 16
AGENTS MODIFYING THE IMMUNE RESPONSE
08/04/2023 17Dr Aaditya
GLUCOCORTICOIDS• First hormonal agents recognized as having
lympholytic properties• Reduces the size and lymphoid content of the
lymph nodes and spleen• Contact hypersensitivity mediated by DTH T cells,
for example, is usually abrogated by glucocorticoid therapy
• Glucocorticoids are first-line immunosuppressive therapy for both solid organ and hematopoietic stem cell transplant recipients, with variable results
• Also used in variety of conditions like SLE, asthma 08/04/2023 18Dr Aaditya
IMMUNOPHILIN LIGANDS• Cyclosporine
– Peptide antibiotic early stage in the antigen receptor-induced differentiation of T cells and blocks their activation
– Binds to cyclophilin (a class of intracellular proteins called immunophilins)
– Inhibits the cytoplasmic phosphatase, calcineurin, which is necessary for the activation of a T-cell-specific transcription factor
– This transcription factor, NF-AT, is involved in the synthesis of interleukins (eg, IL-2) by activated T cells
– Cyclosporine inhibits the gene transcription of IL-2, IL-3, IFN-g08/04/2023 19Dr Aaditya
IMMUNOPHILIN LIGANDS• Tacrolimus
– It is not chemically related to cyclosporine, but their mechanisms of action are similar
– Tacrolimus binds to the immunophilin FK-binding protein (FKBP) inhibits calcineurin
– Tacrolimus is 10-100 times more potent than cyclosporine in inhibiting immune responses
• Both tacrolimus and cyclosporine are extensively used along with glucocorticoids for the suppression of immune response in cases of solid organ transplantation
08/04/2023 20Dr Aaditya
PROLIFERATION SIGNAL INHIBITOR• Sirolimus (Rapamycin):
– Binds to FK-506 binding protein 12– It blocks molecular target of Rapamycin (mTOR) leads
to inhibition of interleukin driven T-cell proliferation – It is a potent inhibitor of B-cell proliferation and
immunoglobulin production– Also inhibits the mononuclear cell proliferative response
to colony-stimulating factors– Sirolimus-eluting coronary stents have been shown to
reduce re-stenosis– Uses: combination therapy in solid organ transplant,
management of Uveo-retinitis,
A derivative of sirolimus, everolimus, is a proliferation-signal inhibitor that may be of benefit in decreasing rejection in cardiac transplantationIt is being investigated for chronic cardiac allograft vasculopathy
08/04/2023 21Dr Aaditya
ADR• Glucocorticoids:
– Iatrogenic Cushing's Syndrome, Adrenal Suppression, Peptic Ulcers, Bacterial And Mycotic Infections, Myopathy
• Immunophilin Ligands:– Cyclosporine: Nephrotoxicity, Hypertension, Hyperglycemia,
Liver Dysfunction, Hyperkalemia, Altered Mental Status, Seizures, And Hirsutism
– Tacrolimus: nephrotoxicity, neurotoxicity, hyperglycemia, hypertension, hyperkalemia, and gastrointestinal complaints
• Sirolimus and Everolimus: Profound Myelosuppression (Especially Thrombocytopenia), Hepatotoxicity, Diarrhoea, Hypertriglyceridemia, And Headache
08/04/2023 22Dr Aaditya
MYCOPHENOLATE MOFETIL• It inhibits T- and B-lymphocyte responses, including
mitogen and mixed lymphocyte responses, probably by inhibition of de novo synthesis of purines
• Used to treat steroid-refractory graft-versus-host disease in hematopoietic stem cell transplant patients
• Toxicities: Gastrointestinal Disturbances (nausea and vomiting, diarrhea, abdominal pain) Headache, Hypertension and Reversible Myelosuppression (Primarily Neutropenia)
08/04/2023 23Dr Aaditya
THALIDOMIDE• It has significant immunomodulatory actions and is
currently studied for over 40 different illnesses• Currently used in the treatment of multiple
myeloma at initial diagnosis and for relapsed-refractory disease
• Response rates from 20 to 70%• The most important toxicity is teratogenesis.• Other adverse effects of thalidomide include
peripheral neuropathy, constipation, rash, fatigue, hypothyroidism, and increased risk of deep vein thrombosis
08/04/2023 24Dr Aaditya
IMiDs• Immunomodulatory derivatives of thalidomide• Lenalidomide is an IMiD that in animal and in vitro
studies has been shown to be similar to thalidomide in action, but with less toxicity, especially teratogenicity
• Showed its effectiveness in the treatment of the myelodysplastic syndrome with the chromosome 5q31 deletion
• CC-4047 (Actimid) is another IMiD that is being investigated for the treatment of myelodysplastic syndrome, myeloma, and prostate cancer.
Selective cytokine inhibitory drugs (SelCIDs), are phosphodiesterase type 4 inhibitors with potent anti-TNF-α activity but no T-cell co-stimulatory activity
08/04/2023 25Dr Aaditya
Immunostimulants• Immunostimulants are substances that modulate the
immune system by stimulating the function of one or more of the system’s components
• Classified as– Biological response modifyers
• BCG• Levamisole• Thalidomide
– Recombinant proteins• Interferons
– Immunization – Others
• Thymosin• Immunocynin 08/04/2023 26Dr Aaditya
• Auto immune diseases:– Traditionally only immunodepressents were used– Low dose naltrexone (LDN) has been used in the treatment of
multiple sclerosis– Inosine Pranobex/Isoprinosine (Imunovir) may be helpful in
rheumatic diseases (lupus/SLE, rheumatoid arthritis), multiple sclerosis and alopecia areata
• IGIV used in the treatment of many disorders• β-Glucans (beta-glucans), echinacea are tried in
cancer, radiation, shock, prevention of infection, wound healing, etc.
08/04/2023 27Dr Aaditya
Recent advances in Immunostimulants
ANTIBODIES IN CLINICAL USE
08/04/2023 28Dr Aaditya
POLYCLONAL ANTIBODIES
• Antilymphocyte antibodies (ALG)
• Antithymocyte antibodies(ATG)
• Immune globulin Intravenous (IGIV)
• Hyperimmune immunoglobulins
08/04/2023 29Dr Aaditya
ATG AND ALG• Obtained by immunization of large animals
such as horses with human lymphoid cells• They lead to destruction of T cells and
impairment of cell mediated immunity• ATG for treatment of acute renal transplant
rejection ( 1.5 mg/kg per day for 7 -14 days) and for preparation of bone marrow transplantation
• ALG for preparation of bone marrow transplantation
08/04/2023 30Dr Aaditya
IGIV• Nonspecific polyclonal human
immunoglobulin
• Prepared from pools of healthy donors
• Leads to reduction in helper T cells, increase in suppressor T cells, and decrease in spontaneous Ig production
• Found to be useful in variety of immune syndromes ranging like ITP and SLE
08/04/2023 31Dr Aaditya
HYPERIMMUNE Ig
• IGIV prepared from pools of selected human and animal donors
• High titers of antibodies against a particular agent of interest
• Used for the prevention or treatment of various infections such as rabies, tetanus, CMV infections, hepatitis B virus
08/04/2023 32Dr Aaditya
OTHER PUTATIVE APPLICATIONS• Blocking the action of cell surface receptors
• Receptor binding and antagonism
• Induction of apoptosis, ADCC and CDC
• Inhibition of viral fusion and replication
• Induction of cell death by radiations
08/04/2023 33Dr Aaditya
MONOCLONAL ANTIBODIES (mAb)
• Antibodies produced from single clone of B cells
• More selective and specific
• Less toxic
• Can be produced on a large scale without compromising the uniformity of the product
08/04/2023 34Dr Aaditya
FIRST MONOCLONAL ANTIBODY•Was produced by Köhler and Milstein in 1975•Technique was somatic cell hybridization•Nobel prize in 1984 for Physiology and Medicine
08/04/2023 35Dr Aaditya
08/04/2023 Dr Aaditya 36
LIMITATIONS
• Human immune response – HAMA
• Gradually reducing efficacy
• Renal damage
• Weak interactions between mouse antibody and human FcγRs (reduced effector function)
• Mouse antibodies do not bind to human FcRn receptors ( reduced half life)
08/04/2023 37Dr Aaditya
SOLUTION
• Chimeric antibodies (-ximabs) – Variable region of mouse antibody with constant region of human antibody
Eg. Infliximab, Rituximab,Abciximab
• Humanized antibodies (- zumabs)– CDRs from a mouse antibody attached to human antibody.
Eg. Daclizumab,
08/04/2023 38Dr Aaditya
HUMAN MONOCLONAL ANTIBODIES
Transgenic mice Eg. Ipilimumab
Phage display libraries Eg. Adalimumab
Limitation – Lack of species cross reactive antibodies08/04/2023 39Dr Aaditya
MUROMONAB-CD3
• Murine monoclonal antibody Directed against the CD3 molecule on the surface of human thymocytes and mature T cells
• muromonab-CD3 blocks killing by cytotoxic human T cells and several other T-cell functions
• It has proved more effective at reversing acute rejection than conventional steroid treatment
08/04/2023 40Dr Aaditya
ANTIBODIES AGAINST TUMOURS
08/04/2023 41Dr Aaditya
Antitumor MABs• Alemtuzumab is a humanized IgG1 with a kappa chain that
binds to CD52 found on normal and malignant B and T lymphocytes, NK cells, monocytes, macrophages, and a small population of granulocytes.– Approved for the treatment of B-cell chronic lymphocytic leukemia– Patients receiving this antibody become lymphopenic and may also
become neutropenic, anemic, and thrombocytopenic
• Bevacizumab is a humanized IgG1 monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits VEGF from binding to its receptor– Antiangiogenic drug inhibit angiogenesis in tumors– First-line treatment of patients with metastatic colorectal cancer
alone or in combination with 5-FU-based chemotherapy– Adverse events: hemorrhage, gastrointestinal perforations, 08/04/2023 42Dr Aaditya
Antitumor MABs• Cetuximab is a human-mouse chimeric monoclonal
antibody that targets epidermal growth factor receptor (EGFR) – Indicated for use in patients with metastatic colorectal cancer
whose tumours over express EGFR
• Gemtuzumab is a humanized IgG4 monoclonal antibody with a kappa light chain specific for CD33 (a sialoadhesion protein found on leukemic blast cells ) – Gemtuzumab is coupled to the cytotoxic agent, ozogamicin– Is approved for the treatment of patients 60 years and older in
first relapse with CD33 acute myelogenous leukemia – Adverse events severe myelosuppression, significant
hepatotoxicity 08/04/2023 43Dr Aaditya
Antitumor MABs• Rituximab: Chimeric murine-human monoclonal IgG1
(human Fc) that binds to the CD20 molecule on normal and malignant B lymphocytes– Approved for the therapy of patients with relapsed or refractory
low-grade or follicular, B-cell non-Hodgkin's lymphoma– drug appears to be synergistic with chemotherapy (eg,
fludarabine, CHOP) for lymphoma
• Trastuzumab is a recombinant DNA-derived, humanized monoclonal antibody that binds to the extracellular domain of the human epidermal growth factor receptor HER-2/neu– Blocks the natural ligand from binding and down-regulates the
receptor– Metastatic breast cancer in patients whose tumors overexpress
HER-2/neu08/04/2023 44Dr Aaditya
MABs Used to Deliver Isotopes to Tumours
• Arcitumomab is a murine F(ab’)2 fragment from an anti-carcinoembryonic antigen (CEA) antibody labelled with technetium 99m (99mTc) that is used for imaging patients with metastatic colorectal carcinoma (immunoscintigraphy) to determine extent of disease
• Capromab pendetide is a murine monoclonal antibody specific for prostate specific membrane antigen– coupled to isotopic indium (111In)– Used in immunoscintigraphy for patients with biopsy-confirmed
prostate cancer
08/04/2023 45Dr Aaditya
MABs Used to Deliver Isotopes to Tumours
• Ibritumomab tiuxetan is an anti-CD20 murine monoclonal antibody labeled with isotopic yttrium (90Y) or 111In– Radiation provides the major antitumor activity– Approved for use in patients with relapsed or refractory low-
grade, follicular, or B-cell non-Hodgkin's lymphoma, including patients with rituximab-refractory follicular disease
• Nofetumomab is a mouse monoclonal antibody coupled to 99mTc that is used for diagnostic purposes– It binds a 40 kD antigen found on many tumor cell types, but also
on some normal cells– Accurate indicator of extent of disease in biopsy-confirmed small
cell lung cancer except in those patients with brain or adrenal metastases08/04/2023 46Dr Aaditya
MABs Used to Deliver Isotopes to Tumours
• Tositumomab is an anti-CD20 monoclonal antibody and is complexed with iodine 131 (131I)– Two-step therapy in patients with CD20-positive, follicular non-
Hodgkin's lymphoma whose disease is refractory to rituximab and standard chemotherapy
– Toxicities: Severe Cytopenias such as thrombocytopenia and neutropenia
• Satumomab is a murine monoclonal IgG1 antibody that binds to Tumour Associated Glycoprotein – 2 (TAG- 2) expressed on colorectal and ovarian adenocarcinomas– It is labelled with 111In Chloride – Used to diagnostically determine extent of cancer 08/04/2023 47Dr Aaditya
MABs USED AS IMMUNO-SUPPRESSANTS AND ANTI-INFLAMMATORY AGENTS
08/04/2023 48Dr Aaditya
ANTI-TNF-ALPHA MABS• Blocking TNF-a from binding to TNF receptors on
inflammatory cell surfaces results in suppression of downstream inflammatory cytokines such as IL-1 and IL-6 and adhesion molecules involved in leukocyte activation and migration.
• An increased risk of lymphoma is common to such agents• Adalimumab is a completely human IgG1 approved for use
in rheumatoid arthritis– Adalimumab blocks the interaction of TNF-α with TNF receptors
on cell surfaces; it does not bind TNF-β– Administration of adalimumab reduces levels of C- reactive
protein, Erythrocyte Sedimentation Rate, Serum IL-6 and Matrix Metalloproteinases MMP-1 and MMP-3
08/04/2023 49Dr Aaditya
ANTI-TNF-ALPHA MABS• Etanercept is a dimeric fusion protein composed of human
IgG1 constant regions (CH2, CH3, and hinge, but not CH1) fused to the TNF receptor– It binds to both TNF-α and TNF-β and appears to have effects
similar to that of infliximab– Etanercept is approved for adult RA, Polyarticular-course Juvenile
RA, and Psoriatic Arthritis
• Infliximab is a human-mouse chimeric IgG1 monoclonal antibody– Approved for use in Crohn's disease, ulcerative colitis,
rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
08/04/2023 50Dr Aaditya
ALEFACEPT• It is an engineered protein consisting of the CD2-
binding portion of leukocyte-function-associated antigen-3 (LFA-3) fused to a human IgG1 Fc region (hinge, CH1, and CH2), approved for the treatment of plaque psoriasis
• It inhibits activation of T cells by binding to cell surface CD2, inhibiting the normal CD2/LFA-3 interaction
EFALIZUMAB• Recombinant humanized anti-CD11a monoclonal
antibody Withdrawn due to PML
08/04/2023 51Dr Aaditya
BASILIXIMAB• It is a chimeric mouse-human IgG1 that binds to
CD25, the IL-2 receptor alpha chain on activated lymphocytes
• It functions as an IL-2 antagonist Immunosuppressant
DACLIZUMAB• It is a humanized IgG1 that binds to the alpha subunit
of the IL-2 receptor• Its indications are identical to that of basiliximab
08/04/2023 52Dr Aaditya
OMALIZUMAB• It is an anti-IgE recombinant humanized monoclonal
antibody that is approved for the treatment of allergic asthma in adult and adolescent patients whose symptoms are refractory to inhaled corticosteroids
• Abciximab is a Fab fragment of a murine-human monoclonal antibody that binds to the integrin GPIIb/IIIa receptor on activated platelets and inhibits fibrinogen, von Willebrand factor, and other adhesion molecules from binding to activated platelets, thus preventing their aggregation
• Palivizumab is a monoclonal antibody that binds to the fusion protein of RSV, preventing infection in susceptible cells in the airways08/04/2023 53Dr Aaditya
FUTURE• Fully humanized monoclonal antibodies Epilimumab CTLA4 specific Denosumab RANK ligand specific Zanolimumab CD4 specific Golimumab TNF specific
• PEGylation of fragments certolizumab pegol for Crohn’s disease
• Abdegs – antibodies that increase IgG degradation
5503/03/2007 Monoclonal antibodies
Humanized MAbsAtlizumabBapineuzumabErlizumab Felvizumab Fontolizumab Inotuzumab ozogamicinLabetuzumabLintuzumabMatuzumabMepolizumabMotavizumabNatalizumab NimotuzumabNolovizumabNumavizumabOcrelizumab
PascolizumabPecfusituzumab Pectuzumab Pertuzumab PexelizumabRalivizumab RanibizumabSibrotuzumabSiplizumabSontuzumab Talizumab Toralizumab Tucotuzumab celmoleukin Umavizumab Urtoxazumab Visilizumab
Dr Aaditya
TGN1412- a disaster• CD28-SuperMAB• It is a humanised monoclonal antibody that not only binds
to, but is a strong agonist for, the CD28 receptor of the immune system's T cells
• B cell chronic lymphocytic leukemia (B-CLL) and rheumatoid arthritis
• In its first human clinical trials, in March 2006, it caused catastrophic systemic organ failure in the subjects
• Administered at a supposed sub-clinical dose of 0.1 mg per kg, some 500 times lower than the dose found safe in animals
• Hospitalization of six volunteers on 13 March 2006.• One patient developed cancer of the GI tract08/04/2023 56
Interferons in therapy• Have a broad spectrum of antiviral activities as well as
immunomodulating and antiproliferative properties
• Not available orally, must be given IM, SC or IV
• DNA recombinant technology - highly purified interferons
• IFNs when bound to polyethylene glycol (PEG) have substantially longer half lives. Results in stable and sustained concentrations
Adverse events• IFNα – immune mediated disorders, Alopecia
• IFNβ – local necrosis of the skin
• G-CSF – neutrophillic dermatitis08/04/2023 57Dr Aaditya
Interferons in therapy• IFNα2b – Condyloma acuminatum
- Chronic Hepatitis C- Chronic Hepatitis B, Chronic Hepatitis D?
( CML, melanoma, multiple myeloma, renal cell carcinoma)• IFNα2a - Chronic Hepatitis C
- Chronic Hepatitis D- Multiple sclerosis
• IFNαn3 - Condyloma acuminatum
• Pegylated IFNα2b/a - Chronic Hepatitis C
• IFN Alfacon - Chronic Hepatitis C
• IFNγ – Chronic granulamtous diseases- Systemic sclerosis, osteopetrosis
08/04/2023 58Dr Aaditya
Interleukin 2• Exerts its antitumor effects indirectly through
augmentation of its immune function
• High doses can produce tumor regression in cancers like metastatic melanomas and renal cell carcinoma
• About 2 – 5 % patients may experience complete remissions that are durable
• Side effects include: intravascular volume depletion, capillary leak syndrome, ARDS, hypotension, fever, hypersensitivity and impaired liver and renal functions.
08/04/2023 59Dr Aaditya
Interleukin - 11• Interleukin-11 (IL-11) is a cytokine that stimulates
hematopoietic stem cells as well as megakaryocytes, resulting in increased platelet production.
• It is produced commercially (Oprevelkin, Genetics Institute, Cambridge, MA, USA) by recombinant DNA in Escherichia coli.
• The commercial product is a 177 amino acid polypeptide.
• It is indicated for the prevention of severe thrombocytopenia and reduction of platelet transfusions in patients with non-myeloid malignancies
08/04/2023 60Dr Aaditya
GM-CSF (Filgrastim)• GM-CSF was first identified based on its ability to
stimulate the clonal proliferation of myeloid precursors in vitro.
• The biologic effects of GM-CSF are mediated via binding to receptors expressed on the surface of target cells.
• The GM-CSF receptor is expressed on granulocyte, erythrocyte, megakaryocyte, and macrophage progenitor cells as well as mature neutrophils, monocytes, macrophages, dendritic cells, plasma cells, certain T lymphocytes, vascular endothelial cells, uterine cells, and myeloid leukemia cells.08/04/2023 61Dr Aaditya
GM-CSFTherapeutic use Results with rhuGM-CSF
Fungal infections Decreases incidence, as an adjuvant with antifungal and chemotherapy
HIV infection and its complications
Increases CD4 counts, decreases viral load
Vaccine adjuvant Enhances antibody response to Hep C Vaccine. Increases seroconversion in flu vaccines
Antitumor therapy Prolongs disease free survival and overall survival
Immunotherapy for AML
Decreases risk of relapse
Mucositis, stomatitis & diarrhea
Reduces incidence and severity
Wound healing Decreases time to wound healing. Reduces mean ulcer surface area
08/04/2023 62Dr Aaditya
PegFilgrastim• The addition of a 20 kDa polyethylene glycol moiety to filgrastim virtually eliminate renal clearance.
• The major remaining mode of clearance of pegfilgrastim is the neutrophil itself through a ‘self-regulating’ mechanism .
• Single dose of pegfilgrastim after chemotherapy led to a steady state serum concentration of this cytokine during the post chemo-therapy period, through the neutrophil nadir until subsequent neutrophil recovery .
• Pegfilgrastim stimulates the expansion of early myeloid precursors and the more rapid maturation and differentiation of neutrophils.
• As adequate neutrophil recovery occurs, these cells clear pegfilgrastim from the serum through G-CSF receptor–ligand binding over a rapid time course of 24–48 h.
08/04/2023 63Dr Aaditya
PegFilgrastim• Clinical trials are needed to further define the role of pegfil-
grastim with other chemotherapy regimens and in other disease settings, particularly to explore more dose-dense regimens of every 2 weeks or even weekly chemotherapy.
• Although previous trials have administered pegfilgrastim 24 h after chemotherapy, there is interest in examining the dosing of pegfilgrastim on the same day as chemotherapy.
• Furthermore, to take advantage of the self-regulating properties of pegfilgrastim, studies of this agent in the setting of prolonged neutropenia such as the post-transplant setting and acute myeloid leukemia, are of particular interest.
08/04/2023 64Dr Aaditya
Technicalities And Formalities
Patents • The exclusive right of an inventor to manufacture
the product invented by him for a fixed period– Antibodies (murine, humanized or human)– All natural immune components used therapeutically
which are manufactured by a specific process• Interferons (INF-β 1a patent by Biogen, brand name AVONEX)• Interleukins (Oprevelkin)• G-CSF (filgastrim patent by AMGEN, brand name NEUPOGEN)
• www.Iprlawindia.com • www.freepatentsonline.com
08/04/2023 Dr Aaditya 65
Technicalities And Formalities
Laws and guidelines• Guidelines of
– Source of biological substances (origin of feeder cells)– Fusion partner (mylenoma, human lymphoblastoid-B cell
line,etc)– Safety of production of biological substances (viral and
bacterial infections)– All the cell lines should be periodically reviewed and
compared with cryopreserved samples of cell lines– Quality controlProduction And Quality Control Of Monoclonal Antibodies Directive 75/318/EEC Dec06
08/04/2023 Dr Aaditya 66
Technicalities And Formalities
Laws and guidelines• Laws regarding the research of new drugs due to
patent problems• Laws regarding manufacture of drugs due to patent
problems• US FDA has guidelines for the production, storage
and use of biological compounds
08/04/2023 Dr Aaditya 67
08/04/2023 Dr Aaditya 68
Mechanism Of Autoimmunity(1) Exposure of self-reactive T lymphocytes to antigens previously
sequestered from the immune system (eg, lens protein, myelin basic protein).
(2) Molecular mimicry by invading pathogens, in which immune responses are directed at antigenic determinants on pathogens that share identical or similar epitopes with normal host tissue. This phenomenon occurs in rheumatic fever following Streptococcus pyogenes infection, in which heart damage is thought to arise from an immune response directed against streptococcal antigens shared with heart muscle. The suggested viral etiology of autoimmune diseases has been ascribed to immune responses (both cell-mediated and humoral) directed against virus epitopes that mimic sequestered self antigens.
(3) Inappropriate expression of class II MHC molecules on the membranes of cells that normally do not express class II MHC (eg, islet β cells). Increased expression of MHC II may increase presentation of self peptides to T helper cells, which in turn induce CTL, TDTH, and B-lymphocyte cells that react against self antigens08/04/2023 69Dr Aaditya
IMMUNOSUPPRESSIVE ANTIBODIES
• Development of hybridoma technology by Milstein and Kohler in 1975
• Hybridomas consist of antibody-forming cells fused to immortal plasmacytoma cells
• Genetic engineering techniques involve production of chimeric and humanized versions of murine monoclonal antibodies
08/04/2023 70Dr Aaditya
CYTOTOXIC AGENTS• Azathioprine (Antimetabolite) produces
immunosuppression by interfering with purine nucleic acid metabolism at steps that are required for the wave of lymphoid cell proliferation that follows antigenic stimulation
• Cyclophosphamide (Alkylating Agent) destroys proliferating lymphoid cells
• Leflunomide is an inhibitor of pyrimidine synthesis
• Hydroxychloroquine suppress intracellular antigen processing and loading of peptides onto MHC class II molecules by increasing the pH of lysosomal and endosomal compartments, thereby decreasing T-cell activation08/04/2023 71Dr Aaditya
RECENT CYTOTOXIC AGENTS• Ixabepilone
– An analog of epothilone B that blocks tubulin polymerization in a way similar to that of the taxanes
– Is being tried for highly resistant malignant breast cancer and non squamous cell lung cancer
08/04/2023 72Dr Aaditya